Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

EHA 2015

11 - 14 Jun 2015

Reed Messe, Vienna, Austria

Ibrutinib combined with bendamustine plus rituximab in previously treated CLL and SLL

Dr Paula Cramer - University of Cologne, Köln, Germany

Ibrutinib combined with bendamustine plus rituximab in previously treated CLL and SLL ( Dr Paula Cramer - University of Cologne, Köln, Germany )

Chemoresistance and residual disease promoted by DNMT3A R882 in AML

Dr Olga Guryanova - Memorial Sloan Kettering Cancer Center, New York, USA

Chemoresistance and residual disease promoted by DNMT3A R882 in AML ( Dr Olga Guryanova - Memorial Sloan Kettering Cancer Center, New York, USA )

Comment: Venetoclax with rituxumab highly active in relapsed refractory CLL

Prof Anton Hagenbeek - University Medical Center Utrecht, Utrecht, Netherlands

$Comment: Venetoclax with rituxumab highly active in relapsed refractory CLL ( Prof Anton Hagenbeek - University Medical Center Utrecht, Utrecht, Netherlands )$

EHA 2015 highlights

Peter Goodwin - ecancer reporter

EHA 2015 highlights ( Peter Goodwin - ecancer reporter )

Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma

Dr Jessica Okosun - Barts Cancer Institute, London, UK

Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma ( Dr Jessica Okosun - Barts Cancer Institute, London, UK )

Biomarkers for childhood relapsed acute lymphoblastic leukaemia

Prof Anthony Moorman - Newcastle University, Newcastle, UK

Biomarkers for childhood relapsed acute lymphoblastic leukaemia ( Prof Anthony Moorman - Newcastle University, Newcastle, UK )

Are CML patients being treated to the correct standard?

Dr Verena Hoffmann - Ludwig Maximilian University, Munich, Germany

Are CML patients being treated to the correct standard? ( Dr Verena Hoffmann - Ludwig Maximilian University, Munich, Germany )

EHA 2015: Reviewing the treatment landscapes of CLL, MCL, and MM

Prof John Gribben, Prof Marivi Mateos, Prof Umberto Vitolo, Prof Paolo Ghia

EHA 2015: Reviewing the treatment landscapes of CLL, MCL, and MM ( Prof John Gribben, Prof Marivi Mateos, Prof Umberto Vitolo, Prof Paolo Ghia )

Overview of innovation in Hodgkin's lymphoma

Prof Volker Diehl - Winner of the Jean Bernard Lifetime Achievement Award

Overview of innovation in Hodgkin's lymphoma ( Prof Volker Diehl - Winner of the Jean Bernard Lifetime Achievement Award )

Applications of chimaeric antigen receptor T-cells in leukaemia

Dr Carl June - University of Pennsylvania, Philadelphia, USA

Applications of chimaeric antigen receptor T-cells in leukaemia ( Dr Carl June - University of Pennsylvania, Philadelphia, USA )

Minimal residual disease in multiple myeloma

Dr Bruno Paiva - University Clinic of Navarra, Pamplona, Spain

Minimal residual disease in multiple myeloma ( Dr Bruno Paiva - University Clinic of Navarra, Pamplona, Spain )

Immunoconjugates address unmet needs in Hodgkin's lymphoma patients

Prof Anton Hagenbeek - University Medical Center Utrecht, Utrecht, Netherlands

Immunoconjugates address unmet needs in Hodgkin's lymphoma patients ( Prof Anton Hagenbeek - University Medical Center Utrecht, Utrecht, Netherlands )

EHA 2015: Expert opinions on new treatment standard in multiple myeloma

Prof Pieter Sonneveld, Prof Antonio Palumbo, Prof Gordon McVie, Prof Thierry Facon

EHA 2015: Expert opinions on new treatment standard in multiple myeloma ( Prof Pieter Sonneveld, Prof Antonio Palumbo, Prof Gordon McVie, Prof Thierry Facon )

Exploring "bad luck" - why do some patients develop myeloid leukaemia?

Dr George Vassiliou - Cambridge Cancer Centre, Cambridge, UK

Exploring "bad luck" - why do some patients develop myeloid leukaemia? ( Dr George Vassiliou - Cambridge Cancer Centre, Cambridge, UK )

Genomic sequencing to find AML-causing mutations

Dr George Vassiliou - Cambridge Cancer Centre, Cambridge, UK

Genomic sequencing to find AML-causing mutations ( Dr George Vassiliou - Cambridge Cancer Centre, Cambridge, UK )

The latest in multiple myeloma: a European and US perspective

Prof Paul Richardson and Prof Marivi Mateos

The latest in multiple myeloma: a European and US perspective ( Prof Paul Richardson and Prof Marivi Mateos )

Measuring molecular responses to tyrosine kinase inhibitors in chronic myeloid leukaemia

Prof Susan Branford - Adelaide University Adelaide, Australia

Measuring molecular responses to tyrosine kinase inhibitors in chronic myeloid leukaemia ( Prof Susan Branford - Adelaide University Adelaide, Australia )

Advances in the treatment and management of CLL

Prof Clemens Wendtner and Prof Peter Hillmen

Advances in the treatment and management of CLL ( Prof Clemens Wendtner and Prof Peter Hillmen )

Transplantation combined with novel agents optimal treatment for multiple myeloma

Prof Vincent Rajkumar - Mayo Clinic, Rochester, USA

Transplantation combined with novel agents optimal treatment for multiple myeloma ( Prof Vincent Rajkumar - Mayo Clinic, Rochester, USA )

Monoclonal antibodies and multiple myeloma

Prof Vincent Rajkumar - Mayo Clinic, Rochester, USA

Monoclonal antibodies and multiple myeloma ( Prof Vincent Rajkumar - Mayo Clinic, Rochester, USA )

New definition for multiple myeloma improves patient outcomes

Prof Vincent Rajkumar - Mayo Clinic, Rochester, USA

New definition for multiple myeloma improves patient outcomes ( Prof Vincent Rajkumar - Mayo Clinic, Rochester, USA )

Factors influencing response to blinatumomab in relapsed/refractory ALL

Prof Max Topp - Würzburg University Hospital, Würzburg, Germany

$Factors influencing response to blinatumomab in relapsed/refractory ALL ( Prof Max Topp - Würzburg University Hospital, Würzburg, Germany )$

Evidence for kinase inhibitor activity in acute myeloid leukaemia

Dr Gerhard Ehninger - University Hospital Dresden, Dresden, Germany

Evidence for kinase inhibitor activity in acute myeloid leukaemia ( Dr Gerhard Ehninger - University Hospital Dresden, Dresden, Germany )

Targeted combination therapy with potential to eliminate relapsed chronic lymphocytic leukaemia

Dr Andrew Roberts - Royal Melbourne Hospital, Melbourne, Australia

Targeted combination therapy with potential to eliminate relapsed chronic lymphocytic leukaemia ( Dr Andrew Roberts - Royal Melbourne Hospital, Melbourne, Australia )

DNMT3A R882 mutations promote chemoresistance and residual disease in AML

Dr Olga Guryanova - Memorial Sloan Kettering Cancer Center, New York, USA

DNMT3A R882 mutations promote chemoresistance and residual disease in AML ( Dr Olga Guryanova - Memorial Sloan Kettering Cancer Center, New York, USA )

New targeted combination therapy with potential to eliminate relapsed chronic lymphocytic leukaemia

Dr Andrew Roberts - Royal Melbourne Hospital, Melbourne, Australia

New targeted combination therapy with potential to eliminate relapsed chronic lymphocytic leukaemia ( Dr Andrew Roberts - Royal Melbourne Hospital, Melbourne, Australia )

First randomised evidence for kinase inhibitor activity in acute myeloid leukaemia

Dr Gerhard Ehninger - University Hospital Dresden, Dresden, Germany

First randomised evidence for kinase inhibitor activity in acute myeloid leukaemia ( Dr Gerhard Ehninger - University Hospital Dresden, Dresden, Germany )

Does the patient with myelofibrosis feel better through pacritinib?

Dr Ruben Mesa - Mayo Clinic Cancer Center, Scottsdale, USA

Does the patient with myelofibrosis feel better through pacritinib? ( Dr Ruben Mesa - Mayo Clinic Cancer Center, Scottsdale, USA )

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression

Dr Meletios Dimopoulos - National and Kapodistrian University of Athens, Athens, Greece

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression ( Dr Meletios Dimopoulos - National and Kapodistrian University of Athens, Athens, Greece )

Treatment and survival of patients with chronic myeloid leukaemia in Europe

Dr Verena Hoffmann - Ludwig-Maximilians-Universität, München, Germany

Treatment and survival of patients with chronic myeloid leukaemia in Europe ( Dr Verena Hoffmann - Ludwig-Maximilians-Universität, München, Germany )

Expert overview on the recent developments in mantle cell lymphoma

Professor Gordon McVie and Professor Simon Rule

Expert overview on the recent developments in mantle cell lymphoma ( Professor Gordon McVie and Professor Simon Rule )

More from ecancer